Journal of American Association for Pediatric Ophthalmology and Strabismus
Short reportRetrospective analysis of children with uveitis treated with infliximab
Section snippets
Methods
We reviewed the medical records of 20 children with uveitis who had been treated with infliximab between 2002 and 2007. The study population was obtained from the database of the Uveitis Service at the Department of Ophthalmology, Istanbul University, Istanbul Faculty of Medicine, including 78 children with idiopathic intermediate uveitis, 34 with juvenile idiopathic arthritis (JIA)-related uveitis, 20 with idiopathic chronic anterior uveitis, and 26 with Behçet uveitis. Inclusion criteria were
Results
Demographic features, systemic medications, and ocular complications at initiation of infliximab therapy, ocular surgeries performed after the initiation of infliximab therapy, and total number of infliximab infusions are shown in e-Supplement 1, available at jaapos.org. Thirteen patients were male (65%) and 7 were female (35%). The median age at presentation was 7.1 years (range, 3-12 years). Eight patients had idiopathic pars planitis, 7 had JIA-related anterior uveitis, 4 had idiopathic
Discussion
Several authors have reported a favorable response to infliximab therapy in children with uveitis refractory to conventional immunosuppressive therapy.1, 2, 3, 4 In studies comparing the efficacy of infliximab versus etanercept, the former was reported to be superior.5, 6, 7 In the present series, only 1 patient had received etanercept before infliximab for his rheumatic disease. Etanercept was not considered as a first line anti-TNF therapy for uveitis in any of the patients. In previous
References (10)
- et al.
Retrospective case review of pediatric patients with uveitis treated with infliximab
Ophthalmology
(2006) - et al.
Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up
Am J Ophthalmol
(2007) - et al.
Favorable response to high-dose infliximab for refractory childhood uveitis
Ophthalmology
(2006) - et al.
Infliximab for juvenile idiopathic arthritis–associated uveitis
Clin Exp Ophthalmol
(2005) - et al.
Tumour necrosis factor a inhibitors in the treatment of childhood uveitis
Rheumatology (Oxford)
(2006)